PSZ: Devices Detecting Influenza A, B, And C Virus Antigens

Product code PSZ, “Devices Detecting Influenza A, B, And C Virus Antigens” in FDA's classification database, is a Class II device type under 21 CFR 866.3328 (influenza virus antigen detection test system), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 73 clearances under PSZ, 37 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
PSZ
Regulation
21 CFR 866.3328
Class
II
Panel
Microbiology
Clearances
73
Most recent
Sep 4, 2026
Median review, last 2 years
213 days
Third-party review
Not eligible
Implant
No

What it covers

An influenza virus antigen detection test system is a device intended for the qualitative detection of influenza viral antigens directly from clinical specimens in patients with signs and symptoms of respiratory infection.

FDA’s definition of product code PSZ, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K254262Sofia Influenza A+B FIA; Sofia RSV FIA; Sofia Strep A+ FIAOrtho Clinical Diagnostics Inc. (QuidelOrtho)Sep 4, 2026Dual Track
K252283Nano-Check Influenza A+B TestNano-Ditech CorporationJan 15, 2026Dual Track
K250398Innovita Flu A/B Antigen Rapid TestInnovita (Tangshan) Biological Technology Co., Ltd.Jul 3, 2025Traditional
K241188Acucy® Influenza A&B Test with the Acucy® 2 SystemSEKISUI Diagnostics, LLCApr 18, 2025Dual Track
K232434BD Veritor™ System for Rapid Detection of Flu A+B CLIA Waived KitBdDec 5, 2023Traditional
K223016BD VeritorTM System for Rapid Detection of Flu A+B CLIA-Waived KitBdJan 27, 2023Traditional
K192719Osom Ultra Plus Flu A&B Test KitSEKISUI Diagnostics, LLCApr 3, 2020Dual Track
K191514CareStart Flu A&B PlusAccess Bio, Inc.Feb 18, 2020Dual Track
K182001Acucy Influenza A&B Test with the Acucy SystemSEKISUI Diagnostics, LLCDec 17, 2018Dual Track
K182157BioSign Flu A+BPrinceton BioMeditech Corp.Sep 18, 2018Special
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 73 with a free account)

Clearances by year

37 PSZ 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)2213
20252248
20232118
20202223
2018528
20173200
2016329
2015427
2014129
2013828
2012279
2011380

Who submits

15 applicants cleared a PSZ device since 2011. 97% of the clearances went to applicants in United States, then China (3%). By type: Special 57%, Traditional 27% and Dual Track 16%.

ApplicantClearances since 2011
Becton, Dickinson and Company9
Alere Scarborough, Inc.3
Bd3
Becton, Dickinson & CO3
Princeton BioMeditech Corp.3
Quidel Corporation3
SEKISUI Diagnostics, LLC3
Alere Scarborough, Inc D/B/A Binax, Inc.2

How FDA classifies it

Class II (special controls). The special controls for this device are:

(1) The device's sensitivity and specificity performance characteristics or positive percent agreement and negative percent agreement, for each specimen type claimed in the intended use of the device, must meet one of the following two minimum clinical performance criteria:

(i) For devices evaluated as compared to an FDA-cleared nucleic acid based-test or other currently appropriate and FDA accepted comparator method other than correctly performed viral culture method:

(A) The positive percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.

(B) The negative percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.

(ii) For devices evaluated as compared to correctly performed viral culture method as the comparator method:

(A) The sensitivity estimate for the device when testing for influenza A must be at the point estimate of at least 90 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 80 percent. The sensitivity estimate for the device when testing for influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.

(B) The specificity estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.

(2) When performing testing to demonstrate the device meets the requirements in paragraph (b)(1) of this section, a currently appropriate and FDA accepted comparator method must be used to establish assay performance in clinical studies.

(3) Annual analytical reactivity testing of the device must be performed with contemporary influenza strains. This annual analytical reactivity testing must meet the following criteria:

(i) The appropriate strains to be tested will be identified by FDA in consultation with the Centers for Disease Control and Prevention (CDC) and sourced from CDC or an FDA-designated source. If the annual strains are not available from CDC, FDA will identify an alternative source for obtaining the requisite strains.

(ii) The testing must be conducted according to a standardized protocol considered and determined by FDA to be acceptable and appropriate.

(iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling. If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included. The results must be presented as part of the device's labeling in a tabular format, which includes the detailed information for each virus tested as described in the certificate of authentication, either by:

(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where the analytical reactivity testing data can be found; or

(B) In the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.

(4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain:

(i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate. The procedure and location of testing may depend on the nature of the emerging virus.

(ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by:

(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or

(B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.

From 21 CFR 866.3328. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 866.3328 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PSZ clearances declared.

Ask about PSZ

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about PSZ

What is FDA product code PSZ?

Product code PSZ, “Devices Detecting Influenza A, B, And C Virus Antigens” in FDA's classification database, is a Class II device type under 21 CFR 866.3328 (influenza virus antigen detection test system), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 73 clearances under PSZ, 37 of them since 2011.

How many 510(k) clearances are there under PSZ?

FDA’s 510(k) database listed 73 clearances under PSZ as of Oct 29, 2026, 37 of them decided since 2011; the most recent decision was Sep 4, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a PSZ 510(k)?

For the 4 PSZ clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 213 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most PSZ clearances?

Since 2011: Becton, Dickinson and Company (9), Alere Scarborough, Inc. (3), Bd (3), Becton, Dickinson & CO (3) and Princeton BioMeditech Corp. (3). 15 applicants have cleared a PSZ device in that time.

Sources

  1. FDA product classification: PSZ · Product Classification database
  2. 21 CFR 866.3328: Influenza virus antigen detection test system · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for PSZ · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow PSZGet an email when FDA clears, recalls or publishes guidance for PSZ devices.

Know what FDA already cleared.